Mirum Pharmaceuticals (MIRM) Receivables (2021 - 2026)
Mirum Pharmaceuticals (MIRM) posted quarterly Receivables of $133.1 million for Q1 2026, up 38.87% year-over-year from $95.9 million in Q1 2025, and up 7.93% quarter-over-quarter from $123.3 million in Q4 2025.
Mirum Pharmaceuticals (MIRM) Receivables (2021 - 2026) Analysis & Trends
Mirum Pharmaceuticals' Receivables history runs 6 years deep, the most recent figure standing at $133.1 million for Q1 2026.
- In Q1 2026, Receivables rose 38.87% year-over-year to $133.1 million; the TTM figure through Mar 2026 stood at $133.1 million (up 38.87% YoY), while the FY2025 annual figure was $123.3 million, up 57.54% from the prior year.
- Receivables for Q1 2026 stood at $133.1 million, up from $123.3 million in the prior quarter.
- The five-year high for Receivables was $133.1 million in Q1 2026, with the low at $7.9 million in Q1 2022.
- The 5-year median for Receivables is $60.4 million (2024), against an average of $62.7 million.
- The sharpest annual moves came in 2022 and 2024: Receivables surged 3984.25% in 2022, then climbed 15.18% in 2024.
- Mirum Pharmaceuticals' Receivables stood at $24.0 million in 2022, then soared by 183.27% to $68.0 million in 2023, then climbed by 15.18% to $78.3 million in 2024, then jumped by 57.54% to $123.3 million in 2025, then gained by 7.93% to $133.1 million in 2026.
- Business Quant data shows MIRM's Receivables at $133.1 million in Q1 2026, $123.3 million in Q4 2025, and $107.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Mirum Pharmaceuticals | 6.52 Bn | 6.08 Bn | 145.90 Mn | 145.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 145.36 Mn |
| Mar 31, 2026 | 133.11 Mn |
| Dec 31, 2025 | 123.33 Mn |
| Sep 30, 2025 | 107.13 Mn |
| Jun 30, 2025 | 106.84 Mn |
| Mar 31, 2025 | 95.85 Mn |
| Dec 31, 2024 | 78.29 Mn |
| Sep 30, 2024 | 68.53 Mn |
| Jun 30, 2024 | 60.43 Mn |
| Mar 31, 2024 | 55.00 Mn |
| Dec 31, 2023 | 67.97 Mn |
| Sep 30, 2023 | 47.83 Mn |
| Jun 30, 2023 | 35.33 Mn |
| Mar 31, 2023 | 24.66 Mn |
| Dec 31, 2022 | 23.99 Mn |
| Sep 30, 2022 | 16.34 Mn |
| Jun 30, 2022 | 13.99 Mn |
| Mar 31, 2022 | 7.87 Mn |
| Dec 31, 2021 | 3.27 Mn |
| Sep 30, 2021 | 400,000.00 |